Content - HD 21

HD 21 - Alternative chemotherapy-schema for patients with Hodgkin lymphoma

In this trial, we investigate an alternative chemotherapy-schema (a combination of active substances for chemotherapy) for patients with Hodgkin lymphoma (tumor of the lymphatic system). We undertake this trial because while the current standard therapy offers a promising prognosis, it may also cause serious side effects. Therefore, we want to find a chemotherapy-schema that has the same efficacy, but with less, or less serious side effects.  

Currently, the standard chemotherapy for patients who suffer from an advanced state of Hodgkin lymphoma and are younger than 60 years consists of six series of the BEACOPP-schema. BEACOPP identifies a combination of active substances used in the chemotherapy, in this case bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone. We compare this schema in the trial HD 21 with the BrECADD-schema (brentuximab vedotin, etoposide, cyclophosphamide, adriamycin, dacarbazine, dexamethasone). Brentuximab vedotin is an antibody-drug conjugate that tracks tumor cells and directs the cytostatic drug (a substance that constrains cell growth) to the tumor cells. This substance has shown a high efficacy with comparably few or less serious side effects in patients with recurrent Hodgkin lymphoma.  

Patients that suffer from an advanced Hodgkin lymphoma in the stage IIB or IV can be part of this trial.

Study chair:

Dr. med. Alden Moccia, IOSI, +41 91 811 47 64

  • Contacts at the hospitals

  • Inclusion criteria

    • Histologically proven classical Hodgkin lymphoma
    • First diagnosis, no previous treatment, 18 to 60 years of age
    • Stage IIB with large mediastinal mass and/or extranodal lesions, stage III or IV
  • Exclusion criteria

    • Composite lymphoma or nodular lymphocyte-predominant Hodgkin lymphoma
    • Previous malignancy (exceptions: basalioma, carcinoma in situ of the cervix uteri, completely resected melanoma TNMpT1)
    • Prior chemotherapy or radiotherapy

Locations for this trial:

Kantonsspital Aarau
Tellstrasse 25
0 5001 Aarau
Kantonsspital Baden
Im Ergel 1
4600 Baden
Universitätsspital Basel
Petersgraben 4
0 4031 Basel
Istituto Oncologico della Svizzera Italiana IOSI
Via Ospedale
0 6500 Bellinzona
Freiburgstrasse 8
3010 Bern
Kantonsspital Bruderholz
0 4101 Bruderholz
Kantonsspital Graubünden
Loëstrasse 170
7000 Chur
Hôpital Fribourgeois HFR
Chemin des Pensionnats 2
1708 1708 Fribourg
Kantonsspital Liestal
Rheinstrasse 26
0 4410 Liestal
Hôpital neuchâtelois
Chasseral 20
0 2303 La Chaux-de-Fonds
Kantonsspital Olten
Baslerstrasse 150
0 4600 Olten
Kantonsspital St. Gallen
Rorschacher Strasse 95
0 9007 St. Gallen
Spital STS AG Thun
Krankenhausstrasse 12
0 3600 Thun
Kantonsspital Winterthur
Brauerstrasse 15
0 8401 Winterthur
Stadtspital Triemli
Birmensdorferstrasse 497
0 8063 Zürich
Spital Thurgau, Kantonsspital Frauenfeld
Waldeggstrasse 8A
0 8501 Frauenfeld